-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Pulse is compiled and sorted out, please do not reprint
The highly anticipated 58th Annual Meeting of the European Association for the Study of Diabetes (2022EASD) will be held
At present, a study revealed in advance by the conference shows that in overweight/obese people, continuous treatment with semaglutide (2.
Explore: Smeglutide and the potential of diabetes prevention
On June 4, 2021, the FDA approved GLP-1 receptor agonist smeglutide injection for chronic weight management in obese or overweight adults, and its weight loss effect is comparable to surgical treatment, in order to see if it can reduce the risk of type 2 diabetes mellitus (T2D), the researchers reanalyzed 2 trials on smeglutide (STEP1 and STEP4) and predicted participants' risk of T2D in the next 10 years through a highly accurate T2D risk prediction method
➤ STEP1 study: 1961 overweight or obese participants received 2.
➤STEP4 study: 803 overweight or obese participants were treated with smegglutide (2.
Benefits: Semegglutide reduces the risk of diabetes by 61%, and continued treatment maintains benefits
➤Step1, the 10-year risk of T2D in the Smeglutide treatment group decreased by 61% (from 18.
➤ Among step4 participants, the risk score decreased the most in the first 20 weeks (20.
6% to 11.
4%), and the risk of patients who continued to receive smeglutide therapy decreased to 7.
7%; However, the risk of patients switching to placebo increased to 15.
4%, indicating the need for continued treatment with semoglutide to maintain a reduced risk of
T2D.
Summary of this article
In summary, continued treatment with smeglutide can significantly reduce the risk
of T2D in overweight/obese patients with prediabetesis or normal blood sugar.
Source: Diabetologia.
Study shows game-changing obesity drug more than halves risk of type 2 diabetes[EB/OL].
[https://medicalxpress.
com/news/2022-09-game-changing-obesity-drug-halves-diabetes.
html].
2022-09-14.
